Rhenman & Partners Asset Management AB Sells 700 Shares of Medpace Holdings, Inc. (NASDAQ:MEDP)

Rhenman & Partners Asset Management AB trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 9.3% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 6,800 shares of the company’s stock after selling 700 shares during the period. Rhenman & Partners Asset Management AB’s holdings in Medpace were worth $2,259,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Grant Private Wealth Management Inc bought a new stake in shares of Medpace during the fourth quarter valued at approximately $279,000. Trexquant Investment LP boosted its stake in Medpace by 130.6% during the fourth quarter. Trexquant Investment LP now owns 35,501 shares of the company’s stock worth $11,794,000 after buying an additional 20,103 shares in the last quarter. Headlands Technologies LLC bought a new stake in Medpace in the 4th quarter valued at $1,057,000. Geode Capital Management LLC raised its stake in shares of Medpace by 4.5% in the 4th quarter. Geode Capital Management LLC now owns 656,130 shares of the company’s stock valued at $218,031,000 after buying an additional 28,076 shares in the last quarter. Finally, Nemes Rush Group LLC acquired a new position in shares of Medpace in the 4th quarter valued at $86,000. Institutional investors and hedge funds own 77.98% of the company’s stock.

Medpace Stock Performance

Shares of NASDAQ:MEDP opened at $287.11 on Friday. The business has a fifty day moving average of $331.56 and a 200-day moving average of $337.60. Medpace Holdings, Inc. has a twelve month low of $282.42 and a twelve month high of $459.77. The firm has a market cap of $8.75 billion, a PE ratio of 22.73, a price-to-earnings-growth ratio of 3.81 and a beta of 1.45.

Medpace (NASDAQ:MEDP) last posted its quarterly earnings data on Monday, February 10th. The company reported $3.67 earnings per share for the quarter, beating the consensus estimate of $2.96 by $0.71. Medpace had a net margin of 19.17% and a return on equity of 51.48%. On average, analysts anticipate that Medpace Holdings, Inc. will post 12.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts recently weighed in on MEDP shares. Robert W. Baird upped their target price on shares of Medpace from $354.00 to $362.00 and gave the company a “neutral” rating in a research note on Monday, January 27th. Leerink Partnrs upgraded Medpace to a “hold” rating in a research note on Monday, March 24th. Finally, Leerink Partners began coverage on Medpace in a research report on Monday, March 24th. They set a “market perform” rating and a $330.00 target price for the company. Nine research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, Medpace currently has a consensus rating of “Hold” and a consensus price target of $376.30.

About Medpace

Medpace Holdings, Inc engages in the provision of outsourced clinical development services to the biotechnology, pharmaceutical and medical device industries. Its services include medical department, clinical trial management, data-driven feasibility, study-start-up, clinical monitoring, regulatory affairs, patient recruitment and retention, medical writing, biometrics and data sciences, pharmacovigilance, core laboratory, laboratories, clinics, and quality assurance.